SCHEMBL10133528

SCHEMBL10133528

CC1CN(c2cc(F)ccc2NC(=O)c2ccc(NS(=O)(=O)C(C)(C)C)cc2)CC(C)O1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.46
NAMPT P43490 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
HDAC3 O15379 3/20 0.41
NCOR2 Q9Y618 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 1/20 0.41
HPGD P15428 2/20 0.41
WDR5 P61964 3/20 0.41
KDM4E B2RXH2 2/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116205 1.00 LMNA (0.47) LMNAALDH1A1MAPTKMT2ANAMPT
SCHEMBL10116206 0.88 CRHBP (0.43) LMNAALDH1A1MAPTKMT2ACRHBP
SCHEMBL10116487 0.87 KMT2A (0.46) LMNAALDH1A1MAPTKMT2ANAMPT
SCHEMBL13204900 0.87 KMT2A (0.46) LMNAALDH1A1MAPTKMT2ANAMPT
SCHEMBL10133635 0.87 KMT2A (0.46) LMNAALDH1A1MAPTKMT2ANAMPT
SCHEMBL10116266 0.86 CRHBP (0.41) LMNAALDH1A1MAPTKMT2ACRHBP
SCHEMBL10133814 0.86 CRHBP (0.41) LMNAALDH1A1MAPTKMT2ACRHBP
SCHEMBL10116204 0.85 CRHBP (0.42) LMNAALDH1A1MAPTKMT2ACRHBP
SCHEMBL10133534 0.85 CRHBP (0.42) LMNAALDH1A1MAPTKMT2ACRHBP
SCHEMBL10116325 0.85 KDM4E (0.43) LMNAALDH1A1MAPTKMT2ACRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 2068/4885ALDH1A1 4599/4885MAPT 3367/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R LMNA 1857/4885ALDH1A1 4517/4885MAPT 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.